Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV resistance to reverse transcriptase inhibitors.

× No keyword cloud information.

46 in total

1. Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.

Authors: P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205

2. A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors: J Mestres; D C Rohrer; G M Maggiora
Journal: J Comput Aided Mol Des Date: 1999-01 Impact factor: 3.686

3. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Authors: J Ren; L E Bird; P P Chamberlain; G B Stewart-Jones; D I Stuart; D K Stammers
Journal: Proc Natl Acad Sci U S A Date: 2002-10-17 Impact factor: 11.205

4. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.

Authors: Lingling Shen; Jianhua Shen; Xiaomin Luo; Feng Cheng; Yechun Xu; Kaixian Chen; Edward Arnold; Jianping Ding; Hualiang Jiang
Journal: Biophys J Date: 2003-06 Impact factor: 4.033

5. Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence.

Authors: Prakash B Palde; Leslie O Ofori; Peter C Gareiss; Jaclyn Lerea; Benjamin L Miller
Journal: J Med Chem Date: 2010-08-26 Impact factor: 7.446

6. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors: H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal: J Virol Date: 1997-11 Impact factor: 5.103

7. Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors: Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191

Review 8. Antiviral therapy for human immunodeficiency virus infections.

Authors: E De Clercq
Journal: Clin Microbiol Rev Date: 1995-04 Impact factor: 26.132

9. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.

Authors: J Balzarini; M Baba; E De Clercq
Journal: Antimicrob Agents Chemother Date: 1995-04 Impact factor: 5.191

10. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors: J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal: Antimicrob Agents Chemother Date: 1995-05 Impact factor: 5.191